特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
960378

片頭痛治療薬の世界市場 (投与経路別、治療クラス別、地域別):考察と予測、新型コロナウイルス感染症 (COVID-19) の潜在的影響 (2020~2024年)

Global Migraine Drugs Market (by Mode of Administration, Treatment Class & Regions): Insights and Forecast with Potential Impact of COVID-19 (2020-2024)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 107 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
片頭痛治療薬の世界市場 (投与経路別、治療クラス別、地域別):考察と予測、新型コロナウイルス感染症 (COVID-19) の潜在的影響 (2020~2024年)
出版日: 2020年09月14日
発行: Koncept Analytics
ページ情報: 英文 107 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の片頭痛治療薬の市場規模は、2020~2024年に3.7%のCAGRで成長し、2024年には51億米ドルの規模に達する、と予測されています。女性人口の増加やタバコ消費量の増大、ストレスレベルの上昇などが市場の主な促進要因として挙げられていますが、最近では新型コロナウイルス感染症 (COVID-19) の爆発的流行に伴うロックダウンの実施で、ストレスレベルが更に上昇して片頭痛患者も増加しているため、市場は一層の拡大を遂げると見られています。また、新薬の研究開発 (R&D) に多額の資金が投じられており、今後の治験の大幅な進展が期待されています。治療クラス別に見ると、トリプタンに無反応や患者や心血管障害のリスクがある患者を対象とした、クラス初の新規治療薬がまもなく上市される見通しです。

当レポートでは、世界の片頭痛治療薬の市場について分析し、全体的な市場規模の動向見通し (過去・今後5年間分) や、投与経路別・治療クラス別および地域別・国別の詳細動向、主な市場促進・抑制要因、企業間の競争状態・業績比較、主要企業のプロファイル、COVID-19感染拡大による影響などを調査しております。

目次

第1章 概要

  • 片頭痛
  • 片頭痛の種類
  • 片頭痛の段階
  • 診断手順
  • 片頭痛の治療法
  • CGRP (カルシトニン遺伝子関連ペプチド) - 片頭痛治療の新時代

第2章 COVID-19の影響

  • ストレスレベルの上昇
  • 各国政府の医療費支出の増加
  • アルコール消費の増加
  • 手指消毒剤の過剰使用の影響

第3章 世界市場の分析

  • 片頭痛治療薬の市場規模 (金額ベース)
  • 片頭痛治療薬の市場規模、予測値 (金額ベース)
  • 片頭痛治療薬の市場規模:投与経路別 (RoA)
    • 経口薬
    • 注射薬
  • 片頭痛治療薬の市場規模:治療クラス別
    • 急性期治療薬 (頓挫薬)
    • 予防薬
  • 片頭痛治療薬の市場規模:地域別

第4章 地域市場

  • 北米
    • 市場規模 (金額ベース)
    • 市場規模、予測値 (金額ベース)
    • 市場規模:地域別
    • 米国:市場規模 (金額ベース)
    • 米国:予測値 (金額ベース)
  • 欧州
  • アジア太平洋
  • 他の国々 (RoW)

第5章 市場力学

  • 成長促進要因
    • 女性人口の増加
    • たばこ消費量の増加
    • 製薬向け研究開発 (R&D) 費の増加
    • 経済成長の加速
    • 医療費費の増加
    • ストレスレベルの増加
    • 医療上のアンメットニーズ
    • 片頭痛の有病率
  • 主な傾向と動静
    • 製薬・バイオテクノロジー業界での研究開発 (R&D) の増加
    • CGRP標的薬剤:現在開発中のパイプライン製品
    • 反復性片頭痛向けブランド急性治療薬
    • 片頭痛とその治療法についての関心増大
    • 更なる片頭痛治療薬の開発
  • 課題
    • 薬物の副作用
    • 適切な診断の欠如
    • 代替治療の選好の増大
    • 規制上の課題
    • 多額の関連コスト

第6章 競合情勢

  • 世界市場
    • 市場収益額の比較:主要企業間
    • 研究開発費の比較:主要企業間
    • 株式時価総額の比較:主要企業間
  • 米国市場
    • 米国の反復性片頭痛向けCGRP薬市場:普及率の予測 (大手企業の場合)
    • 米国の慢性片頭痛向けCGRP薬市場:市場シェアの予測 (大手企業の場合)

第7章 企業プロファイル

  • Novartis AG
  • Merck and Co.
  • Amgen AG
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • Lundbeck
図表

List of Figures

  • Migraine
  • Diagnosis Procedures
  • Global Government Share on Health Spending (2019-2024)
  • Global Alcoholic Beverage Consumption (2017-2021)
  • Global Migraine Drugs Market by Value (2015-2019)
  • Global Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Mode of Administration (2019)
  • Global Oral Migraine Drugs Market by Value (2015-2019)
  • Global Oral Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Injectable Migraine Drugs Market by Value (2015-2019)
  • Global Injectable Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Treatment Class (2019)
  • Global Abortive Migraine Drugs Market by Value (2015-2019)
  • Global Abortive Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Preventative Migraine Drugs Market by Value (2015-2019)
  • Global Preventative Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Migraine Drugs Market by Regions (2019)
  • North America Migraine Drugs Market by Value (2015-2019)
  • North America Migraine Drugs Market Forecast by Value (2020-2024)
  • North America Migraine Drugs Market by Region (2019)
  • The U.S. Migraine Drugs Market by Value (2015-2019)
  • The U.S. Migraine Drugs Market Forecast by Value (2020-2024)
  • Europe Migraine Drugs Market by Value (2015-2019)
  • Europe Migraine Drugs Market Forecast by Value (2020-2024)
  • Asia Pacific Migraine Drugs Market by Value (2015-2019)
  • Asia Pacific Migraine Drugs Market Forecast by Value (2020-2024)
  • ROW Migraine Drugs Market by Value (2015-2019)
  • ROW Migraine Drugs Market Forecast by Value (2020-2024)
  • Global Female Population (2015-2019)
  • Global Cigarette Consumption (2014-2018)
  • Global Pharmaceutical R&D Spending (2015-2019)
  • Global GDP Per Capita (2014-2018)
  • Global Healthcare Spending Per Capita (2014-2018)
  • Global Pharmaceutical and Biotech M&A (2015-2019)
  • Novartis AG Net Sales and Net Income (2015-2019)
  • Novartis AG Net Sales by Segments (2019)
  • Novartis AG Net Sales by Regions (2019)
  • Merck and Co. Sales and Net Income (2015-2019)
  • Merck and Co. Sales by Segments (2019)
  • Merck and Co. Sales by Regions (2019)
  • Amgen AG Total Revenue and Net Income (2015-2019)
  • Amgen AG Total Revenue by Divisions (2019)
  • Amgen AG Total Revenue by Regions (2019)
  • Eli Lilly and Company Revenue and Net Income (2015-2019)
  • Eli Lilly and Company Revenue by Divisions (2019)
  • Eli Lilly and Company Revenue by Regions (2019)
  • Teva Pharmaceuticals Revenue and Net Loss (Income) (2015-2019)
  • Teva Pharmaceuticals Revenue by Regions (2019)
  • Lundbeck Revenue and Profit (2015-2019)
  • Lundbeck Revenue by Regions (2019)

List of Tables

  • Difference Between Episodic and Chronic Migraine
  • Stages of Migraine
  • Global Share of Adults Experiencing Stress During COVID-19 (2020)
  • Progressing CGRP - Targeting Drug Pipeline
  • Branded Acute Treatment for Episodic Migraine
  • Key Players - Revenue Comparison (2019)
  • Key Players - R&D Expenditure Comparison
  • Key Players - Market Capitalization Comparison (2020)
  • Key Players - The U.S. CGRP Drugs for Episodic Migraine Market Penetration Forecast (2019-2023)
  • Key Players - The U.S. CGRP Drugs for Chronic Migraine Market Share Forecast (2019-2023)
目次

The global migraine market is expected to reach US$5.10 billion in 2024, growing at a CAGR of 3.7%, for the duration spanning 2020-2024. The factors such as growing female population, increasing cigarette consumption, increasing pharmaceutical R&D expenditures, accelerating economic growth, increasing healthcare spending, increasing stress levels, unmet medical needs and prevalence of migraine at high rates would drive the growth of the market. However, the market growth would be challenged by adverse effect of drugs, lack of proper diagnosis, increased preferences for alternative options, regulatory challenges and high cost associated. A few notable trends include, growth in pharmaceutical & biotech merger & acquisition, progressing CGRP targeting drug pipeline, branded acute treatment for episodic migraine, growing awareness regarding migraine and its therapeutics and development of additional migraine therapeutics.

The global migraine market holds a lucrative growth opportunity for the coming future due to the high prevalence rate of migraine among people. Migraine market is expected to witness the advent of first-in-class novel migraine therapeutics, especially meant for patients who are unresponsive to triptans or ones at risk of cardiovascular disorders. A considerable amount of funds are being invested in the research and development of new migraine drugs, in order to make such therapeutics available in market. A number of drugs are under late stage clinical process and some therapeutics are registered for the FDA approval. Launches of new migraines drugs would thereby help the migraine market to grow globally in coming years.

The fastest growing regional market is North America, due to the presence of well established healthcare infrastructure as well as major pharmaceutical players. Increased retail sales of triptans and ergot alkaloids, demanded by the people with acute migraine conditions for the abortive purpose, helped the market to grow at a considerable pace in the region. Europe and Asia Pacific also secured considerable shares in the migraine market, owing to the high prevalence rate of migraine, along with the increased programmes of collaboration and partnership in the pharmaceutical sector. Further, the sudden outbreak of COVID-19, would trigger the stress levels among people, due to the implementation of the lockdown measures, which would elevate the risk of migraine among them and thereby is expected to accelerate the growth of the global migraine market in coming years.

Scope of the report:

  • The report provides a comprehensive analysis of the global monoclonal antibodies market.
  • The major regional markets (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Novartis AG, Merck & Co., AbbVie Inc., Bristol-Myer Squibb and Amgen AG) are also presented in detail.

Key Target Audience:

  • Monoclonal Antibodies Manufacturers
  • Pharmaceuticals and Biopharmaceutical Firms
  • End Users (Hospitals and Research Institutes)
  • Investment Banks
  • Healthcare and Medical Consultants
  • Government Bodies & Regulating Authorities

Table of Contents

1. Overview

  • 1.1 Migraine
  • 1.2 Types of Migraine
  • 1.3 Stages of Migraine
  • 1.4 Diagnosis Procedures
  • 1.5 Migraine Treatment
  • 1.6 CGRP - A New Era of Migraine Treatment

2. Impact of COVID-19

  • 2.1 Rise in Stress Level
  • 2.2 Growth in Government Spending on Healthcare
  • 2.3 Increase in Alcohol Consumption
  • 2.4 Impact of Excessive Use of Hand Sanitizers

3. Global Market Analysis

  • 3.1 Global Migraine Drugs Market by Value
  • 3.2 Global Migraine Drugs Market Forecast by Value
  • 3.3 Global Migraine Drugs Market by Mode of Administration
    • 3.3.1 Global Oral Migraine Drugs Market by Value
    • 3.3.2 Global Oral Migraine Drugs Market Forecast by Value
    • 3.3.3 Global Injectable Migraine Drugs Market by Value
    • 3.3.4 Global Injectable Migraine Drugs Market Forecast by Value
  • 3.4 Global Migraine Drugs Market by Treatment Class
    • 3.4.1 Global Abortive Migraine Drugs Market by Value
    • 3.4.2 Global Abortive Migraine Drugs Market Forecast by Value
    • 3.4.3 Global Preventative Migraine Drugs Market by Value
    • 3.4.4 Global Preventative Migraine Drugs Market Forecast by Value
  • 3.5 Global Migraine Drugs Market by Regions

4. Regional Market

  • 4.1 North America
    • 4.1.1 North America Migraine Drugs Market by Value
    • 4.1.2 North America Migraine Drugs Market Forecast by Value
    • 4.1.3 North America Migraine Drugs Market by Region
    • 4.1.4 The U.S. Migraine Drugs Market by Value
    • 4.1.5 The U.S. Migraine Drugs Market Forecast by Value
  • 4.2 Europe
    • 4.2.1 Europe Migraine Drugs Market by Value
    • 4.2.2 Europe Migraine Drugs Market Forecast by Value
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific Migraine Drugs Market by Value
    • 4.3.2 Asia Pacific Migraine Drugs Market Forecast by Value
  • 4.4 ROW
    • 4.4.1 ROW Migraine Drugs Market by Value
    • 4.4.2 ROW Migraine Drugs Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Growing Female Population
    • 5.1.2 Increasing Cigarette Consumption
    • 5.1.3 Increasing Pharmaceutical R&D Spending
    • 5.1.4 Accelerating Economic Growth
    • 5.1.5 Increasing Healthcare Spending
    • 5.1.6 Increasing Stress Levels
    • 5.1.7 Unmet Medical Needs
    • 5.1.8 Prevalence of Migraine at High Rate
  • 5.2 Key Trends and Developments
    • 5.2.1 Growth in Pharmaceutical and Biotech Merger & Acquisition
    • 5.2.2 Progressing CGRP - Targeting Drug Pipeline
    • 5.2.3 Branded Acute Treatment for Episodic Migraine
    • 5.2.4 Growing Awareness about Migraine and its Treatment
    • 5.2.5 Development of Additional Migraine Therapeutics
  • 5.3 Challenges
    • 5.3.1 Adverse Effects of Drugs
    • 5.3.2 Lack of Proper Diagnosis
    • 5.3.3 Increased Preference for Alternative Therapies
    • 5.3.4 Regulatory Challenges
    • 5.3.5 High Cost Associated

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Key Players - Revenue Comparison
    • 6.1.2 Key Players - R&D Expenditure Comparison
    • 6.1.3 Key Players - Market Capitalization Comparison
  • 6.2 The U.S. Market
    • 6.2.1 Key Players - The U.S. CGRP Drugs for Episodic Migraine Market Penetration Forecast
    • 6.2.2 Key Players - The U.S. CGRP Drugs for Chronic Migraine Market Share Forecast

7. Company Profiles

  • 7.1 Novartis AG
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Merck and Co.
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Amgen AG
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Eli Lilly and Company
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Teva Pharmaceuticals
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 Lundbeck
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.